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S U M M A R Y
Endocarditis due to Proteus species is very rare. We report a case of endocarditis due to Proteus mirabilis
that was successfully treated with ampicillin and gentamicin, and review the treatment regimens of
previously published cases of Proteus endocarditis.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Endocarditis due to Proteus species is very uncommon, and the
optimal antimicrobial treatment regimen for this infection is
unknown. Although cases of Proteus endocarditis have previously
been reported, a review of antimicrobial treatment regimens
administered to patients with Proteus endocarditis is lacking. We
therefore report a case of Proteus mirabilis endocarditis that was
successfully treated with ampicillin and gentamicin, and review
the literature to summarize the treatment regimens of previously
published cases of Proteus endocarditis.
2. Case report
A 62-year-old female group home resident with cerebral palsy
presented toanoutsidehospitalwithalteredmental statusand fever
for 3 days. At the time of hospital admission, her temperature was
40.6 8C, blood pressure 95/67 mmHg, and heart rate 97 beats per
minute. Physical examination revealed a grade III/VI holosystolic
murmur, best heard at the apex. Laboratory evaluation was
signiﬁcant for an elevated creatinine of 2.1 mg/dl. Urinalysis
revealed ‘too numerous to count’ leukocytes per high-power ﬁeld.
Urinary tract infection was suspected and vancomycin and
ceftazidime were initiated. Admission blood cultures grew Gram-
negative bacilli in two of two sets and the antibiotic regimen was
changed to doripenem on hospital day 2. Computed tomography of
the abdomen and pelvis did not reveal hydronephrosis or
nephrolithiasis. Two sets of blood cultures (four of four bottles)* Corresponding author. Tel.: +1 856 757 7967; fax: +1 856 968 9587.
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subsequently grew P.mirabilis susceptible to ampicillin, gentamicin,
cefazolin, ceftriaxone,meropenem, levoﬂoxacin, and trimethoprim/
sulfamethoxazole; the isolate was resistant to nitrofurantoin. The
admission urine culture also grew P. mirabilis with an identical
antimicrobial susceptibility pattern as the blood isolate. The
patient’s fever resolvedbyhospital day4, and the antibiotic regimen
was changed to intravenous ampicillin. On hospital day 5, she
developed hypotension requiring vasopressor support. Blood
cultures were repeated on hospital day 5 and were negative. A
transesophageal echocardiogram performed on hospital day 6
revealed anterior mitral valve leaﬂet thickening with a central
lucency, consistent with a focal medial scallop abscess, with
moderate mitral valve regurgitation, and no annular extension.
The patient was transferred to our institution on hospital day 7 for
consideration of mitral valve replacement surgery.
On admission to our institution, the patient continued to have
hypotension and required endotracheal intubation because of a
depressed level of consciousness. She did not have evidence of
pulmonary edema or peripheral embolic lesions. Ampicillin, 2 g
intravenously every 4 h, and gentamicin, 1.5 mg/kg intravenously
every 12 h were initiated. Although the patient had an indication
for valvular surgery, shewas considered a poor operative candidate
and thus surgery was not performed. She was successfully weaned
from mechanical ventilation and her subsequent hospital course
was uncomplicated. The serum creatinine decreased to between
1.1 and 1.4 mg/dl, and the gentamicin dosage was adjusted
accordingly to maintain a serum gentamicin trough level below 1.
The patient completed 6 weeks of intravenous antibiotic therapy
with ampicillin and gentamicin and did not have a relapse of P.
mirabilis bacteremia over the 2 weeks following completion of
antibiotic therapy.ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Clinical characteristics, treatment, and outcome of previously published cases of endocarditis due to Proteus speciesa
Age/ gender
(Ref.)
Yearb Urine culture /
chronic urinary
catheter /
nephrolithiasis
Blood
culture
isolate
Antimicrobial
susceptibility
(Proteus blood
isolate)
Valve involved Complicationsc Antibiotic therapy
(duration)
Surgical
intervention
Outcome Follow-upd
62/F
(current)
2010 P. mirabilis / no / no P. mirabilis AMP (S), GENT (S),
CEFTR (S)
Native MV MV abscess AMP+GENT (6 weeks) No Cure 2 weeks
58/F (2) 2007 P. mirabilis / no / yes P. mirabilis ‘Pan-sensitive’ Native MV Possible retinal artery
embolism
CEFTR (4 weeks) No Cure 12 months
64/M (3) 2005 Negative / no / yes P. mirabilis AMP (S), GENT (S),
CEFTR (S)
Native MV Moderate to severe mitral
regurgitation
CEFTR (3 weeks) MV replacement
(HD 22)
Cure 3 months
50/F (4) 2000 P. mirabilis / no /
Unknown
P. mirabilis Unknown Prosthetic AV
(mechanical)
Perivalvular leak, para-aortic
abscess, aorto-atrial ﬁstula,
complete heart block
‘‘Therapy for
Gram-negative
organisms’’
Attempted AV
replacement
Death Death during
AV surgery
25/F (5) 2000 Unknown / no / yes P. mirabilis Unknown Native MV Mitral valve perforation,
pulmonary edema,
splenic infarcts
CEFOTAX+OFLOX
(6 weeks)
MV replacement
(HD 8)
Cure None
45/M (6) 1977 P. mirabilis / no /
Unknown
P. mirabilis AMP (S),e
CARBENIC (S),
GENT (S), KANA (S)
Native MV Cerebral microabscesses AMP+GENT (12 days),
followed by CARBENIC+
KANA (3 days)
No Death Death on HD
18 due to
aspiration
52/F (7) 1973 Unknown / unknown /
unknown
P. mirabilis Unknown Native MV Unknown CHLORAM (unknown) No Death None
55/F (8) 1950 Unknown / no /
unknown
Proteus
group
Unknown Left atrial
wall vegetation
Splenic abscesses PCN+STREP (27 days) No Death Death on HD 27
due to cerebral
embolism
M, male; F, female; AMP, ampicillin; GENT, gentamicin; CEFTR, ceftriaxone; CARBENIC, carbenicillin; KANA, kanamycin; CEFOTAX, cefotaxime; OFLOX, oﬂoxacin; CHLORAM, chloramphenicol; PCN, penicillin; STREP, streptomycin;
AV, aortic valve; MV, mitral valve; HD, hospital day.
a Published cases of Proteus endocarditis that provided clinical details in the publication and that fulﬁlled the modiﬁed Duke criteria for deﬁnite or possible endocarditis.1.
b Year of case report.
c Complications deﬁned as congestive heart failure; valve dehiscence, perforation, rupture, or ﬁstula; perivalvular abscess; or embolic events.
d Follow-up time without relapse after completion of antibiotic therapy, unless otherwise speciﬁed.
e Resistance to ampicillin developed after 12 days of therapy with ampicillin and gentamicin.
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A review of the PubMed database (all languages) for cases of
infective endocarditis due to Proteus species was performed
through the end of July 2010 and included the following individual
search terms: ‘Proteus’, ‘Proteus mirabilis’, ‘Proteus species’, ‘Gram-
negative rods’, and ‘non-HACEK’. Each of the above mentioned
search terms were individually combined with the search terms
‘endocarditis’ and ‘bacteremia’. We also searched the reference
section of each case report of Proteus endocarditis for additional
cases. An article was included in our review if it described a case of
endocarditis due to Proteus species that fulﬁlled themodiﬁed Duke
criteria for deﬁnite or possible infective endocarditis.1 Case reports
or cases that were published as part of a case series that did not
include sufﬁcient clinical details about treatment and outcome
were excluded from this review.
In addition, a searchwas performed using the Cooper University
Hospital medical record system for cases of endocarditis due to
Proteus species that occurred from 1998 to 2010 at our institution.
4. Results
We found seven previously published cases of Proteus
endocarditis in the PubMed database that fulﬁlled our search
criteria (Table 1).2–8 The medical record database search at our
institution did not reveal any patients with a diagnosis of Proteus
endocarditis from 1998 to 2010. There were additional cases of
endocarditis caused by Proteus species published in case series;
however, sufﬁcient clinical details about treatment and outcome
were lacking.9–13 In one of the largest studies performed to date of
2761 cases of deﬁnite infective endocarditis, only three (0.1%)
cases were caused by Proteus species, and details regarding
treatment and outcome were not available.12
Of the eight cases of Proteus endocarditis in our review
(including our case), seven were caused by P. mirabilis; the single
case from 1950 was not identiﬁed to the species level (Table 1). Six
cases fulﬁlled the modiﬁed Duke criteria for deﬁnite infective
endocarditis,2,4–8 while two cases, including the current case,
fulﬁlled criteria for possible infective endocarditis.3 Four of the
eight cases had a positive urine culture for P. mirabilis; one case had
evidence of urinary tract infection on urinalysis, but a urine culture
result was not reported.5 None of the patients had a chronic
indwelling urinary catheter. Nephrolithiasis was reported in three
patients. One of eight cases had a prosthetic valve.
With respect to antimicrobial treatment, of the seven patients
with speciﬁc antimicrobial details reported (including our patient),
four patients were given combination therapy with a beta-lactam
agent plus either an aminoglycoside (n = 3) or a ﬂuoroquinolone
(n = 1); three patients were given monotherapy with either
ceftriaxone (n = 2) or chloramphenicol (n = 1). Evaluation for
synergistic antimicrobial combinations was performed in only
one case report, which revealed evidence for in vitro synergism
between carbenicillin and kanamycin.6 Three patients underwent
surgical intervention. Four of eight patients died. We did not have
sufﬁcient sample size to assess for an association between the type
of antimicrobial treatment regimen administered, or whether
surgery was performed, and outcome.
5. Discussion
We have reported herein a case of endocarditis due to P.
mirabilis that was successfully treated with ampicillin and
gentamicin, and have reviewed the treatment regimens and
outcomes of seven previously published cases of Proteus
endocarditis. Notably, our case was only the second patientreported in the literature who was successfully treated with
antimicrobial therapy alone without valvular surgery.
The optimal antimicrobial treatment regimen for Proteus
endocarditis is unknown. The most recent scientiﬁc statement
on infective endocarditis from the American Heart Association
published in 2005 recommends that combination therapy with
either ampicillin (2 g intravenously every 4 h) or penicillin (20
million units intravenously daily) or a broad-spectrum cephalo-
sporin, plus an aminoglycoside, usually gentamicin (1.7 mg/kg
intravenously every 8 h) be given for endocarditis caused by
susceptible strains of P. mirabilis.14 The rationale behind this
recommendation is that synergism has been demonstrated with
certain combinations of beta-lactams and aminoglycosides.6,14 We
are not aware, however, of clinical trials, cohort studies, or case–
control studies that provide evidence that combination antimicro-
bial therapy with a beta-lactam agent plus an aminoglycoside or a
ﬂuoroquinolone is associated with improved clinical outcome.
Because of the limited number of cases of Proteus endocarditis
found in our reviewwith available details regarding treatment and
outcome, we could not perform an analysis of the efﬁcacy of
monotherapy versus combination antimicrobial therapy.
In conclusion, endocarditis due to Proteus is rare, and the
optimal antimicrobial treatment regimen is unknown. Current
recommendations suggest combination antimicrobial therapy
with a beta-lactam plus an aminoglycoside because of the
potential for synergism;14 however, in one case in our review,
ceftriaxone monotherapy led to cure without requiring surgical
intervention.2 Additional studies with larger numbers of Proteus
endocarditis cases are needed to assess for an association between
speciﬁc antimicrobial treatment regimens and outcome.
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